<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">9706389</journal-id><journal-id journal-id-type="pubmed-jr-id">20773</journal-id><journal-id journal-id-type="nlm-ta">Int J Tuberc Lung Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Tuberc. Lung Dis.</journal-id><journal-title-group><journal-title>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</journal-title></journal-title-group><issn pub-type="ppub">1027-3719</issn><issn pub-type="epub">1815-7920</issn></journal-meta><article-meta><article-id pub-id-type="pmid">24670571</article-id><article-id pub-id-type="pmc">6223014</article-id><article-id pub-id-type="doi">10.5588/ijtld.13.0243</article-id><article-id pub-id-type="manuscript">NIHMS991654</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Diagnosis of paediatric tuberculosis using sputum induction in Botswana: programme description and findings</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Joel</surname><given-names>D. R.</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A2">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Steenhoff</surname><given-names>A. P.</given-names></name><xref ref-type="aff" rid="A2">&#x02020;</xref><xref ref-type="aff" rid="A3">&#x02021;</xref><xref ref-type="aff" rid="A4">&#x000a7;</xref><xref ref-type="aff" rid="A5">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Mullan</surname><given-names>P. C.</given-names></name><xref ref-type="aff" rid="A6">#</xref></contrib><contrib contrib-type="author"><name><surname>Phelps</surname><given-names>B. R.</given-names></name><xref ref-type="aff" rid="A7">**</xref></contrib><contrib contrib-type="author"><name><surname>Tolle</surname><given-names>M. A.</given-names></name><xref ref-type="aff" rid="A8">&#x02020;&#x02020;</xref><xref ref-type="aff" rid="A9">&#x02021;&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Ho-Foster</surname><given-names>A.</given-names></name><xref ref-type="aff" rid="A4">&#x000a7;</xref><xref ref-type="aff" rid="A5">&#x000b6;</xref></contrib><contrib contrib-type="author"><name><surname>Mabikwa</surname><given-names>V.</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Kgathi</surname><given-names>B. G.</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Ncube</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="A10">&#x000a7;&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Anabwani</surname><given-names>G. M.</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="aff" rid="A8">&#x02020;&#x02020;</xref></contrib></contrib-group><aff id="A1"><label>*</label> Botswana&#x02013;Baylor Children&#x02019;s Clinical Centre of Excellence, Princess Marina Hospital, Gaborone</aff><aff id="A2"><label>&#x02020;</label> Department of Paediatrics, Faculty of Health Sciences, University of Botswana School of Medicine, Gaborone, Botswana</aff><aff id="A3"><label>&#x02021;</label> Children&#x02019;s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA</aff><aff id="A4"><label>&#x000a7;</label> Botswana&#x02013;UPenn Partnership, Gaborone, Botswana</aff><aff id="A5"><label>&#x000b6;</label> Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</aff><aff id="A6"><label>#</label> Children&#x02019;s National Medical Center, Washington, DC</aff><aff id="A7"><label>**</label> Office of HIV/AIDS, US Agency for International Development, Washington, DC</aff><aff id="A8"><label>&#x02020;&#x02020;</label> Baylor College of Medicine, Houston, Texas, USA</aff><aff id="A9"><label>&#x02021;&#x02021;</label> Baylor Children&#x02019;s Foundation&#x02013;Tanzania, Mwanza, Tanzania</aff><aff id="A10"><label>&#x000a7;&#x000a7;</label> Ministry of Health, Botswana National TB Programme, Gaborone, Botswana</aff><author-notes><corresp id="CR1">Correspondence to: Dipesalema Joel, Botswana-Baylor Children&#x02019;s Clinical Centre of Excellence, Plot 1836, Hospital Way, Gaborone, Botswana. Tel: (+267) 7251 0370. Fax: (+267) 319 0079. <email>apsalms@yahoo.com</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>10</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>08</day><month>11</month><year>2018</year></pub-date><volume>18</volume><issue>3</issue><fpage>328</fpage><lpage>334</lpage><!--elocation-id from pubmed: 10.5588/ijtld.13.0243--><abstract id="ABS1"><title>SUMMARY</title><sec id="S1"><title>SETTING:</title><p id="P1">Four public hospitals in Botswana, a high tuberculosis (TB) burden setting.</p></sec><sec id="S2"><title>OBJECTIVES:</title><p id="P2">To assess the feasibility and utility of sputum induction in the diagnosis of paediatric TB.</p></sec><sec id="S3"><title>DESIGN:</title><p id="P3">From 2008 to 2010, children aged &#x02a7d;18 years referred for suspected pulmonary TB underwent sputum induction. Confirmed TB was defined as the presence of at least one of the signs and symptoms suggestive of TB and positive <italic>Mycobacterium tuberculosis</italic> culture. Information on TB-associated symptoms (cough, fatigue, night sweats, low appetite, chest pain, weight loss, haemoptysis and contact with a TB case) was collected for three risk groups: human immunodeficiency virus (HIV) positive children, HIV-negative children aged &#x0003c;3 years and HIV-negative children aged &#x02a7e;3 years.</p></sec><sec id="S4"><title>RESULTS:</title><p id="P4">The median age of the 1394 subjects who underwent sputum induction was 3.8 years (IQR 1.3&#x02013;8.4); 373 (27%) were HIV-positive, 419 (30%) were HIV-negative and 602 (43%) had unknown HIV status. TB was confirmed in 84 (6.0%); cases were more likely to have weight loss, chest pain or TB household contacts. There were no serious complications attributable to sputum induction during and after the procedure; only 0.8% (9/1174) of patients reported minor complications.</p></sec><sec id="S5"><title>CONCLUSIONS:</title><p id="P5">In Botswana, paediatric sputum induction was feasible, safe and assisted bacteriological confirmation in a subgroup of children treated for TB.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000c9;SUM&#x000c9;</title><sec id="S6"><title>CONTEXTE:</title><p id="P6">Quatre h&#x000f4;pitaux publics du Botswana, un pays o&#x000f9; la tuberculose (TB) constitue un lourd fardeau.</p></sec><sec id="S7"><title>OBJECTIF:</title><p id="P7">Evaluer la faisabilit&#x000e9; et l&#x02019;utilit&#x000e9; de l&#x02019;expectoration provoqu&#x000e9;e pour le diagnostic de la TB p&#x000e9;diatrique.</p></sec><sec id="S8"><title>SCH&#x000c9;MA:</title><p id="P8">De 2008 &#x000e0; 2010, des enfants &#x000e2;g&#x000e9;s de &#x0003c;18 ans r&#x000e9;f&#x000e9;r&#x000e9;s pour suspicion de TB pulmonaire ont eu une expectoration provoqu&#x000e9;e. La confirmation de la TB &#x000e9;tait d&#x000e9;finie comme la pr&#x000e9;sence d&#x02019;au moins un des signes ou sympt&#x000f4;mes suggestifs de TB ainsi qu&#x02019;une culture positive de <italic>Mycobacterium tuberculosis.</italic> Des donn&#x000e9;es relatives aux sympt&#x000f4;mes (toux, fatigue, sueurs nocturnes, anorexie, douleurs thoraciques, perte de poids, h&#x000e9;moptysie et contact avec un patient tuberculeux) ont &#x000e9;t&#x000e9; recueillies dans trois groupes &#x000e0; risque : enfants au virus de l&#x02019;immunod&#x000e9;ficience humaine (VIH) positif, enfants VIH-n&#x000e9;gatifs &#x000e2;g&#x000e9;s de &#x0003c;3 ans et enfants VIH-n&#x000e9;gatifs &#x000e2;g&#x000e9;s de &#x02a7e;3 ans.</p></sec><sec id="S9"><title>R&#x000c9;SULTATS:</title><p id="P9">Des 1394 enfants qui ont eu une expectoration provoqu&#x000e9;e, l&#x02019;&#x000e2;ge m&#x000e9;dian &#x000e9;tait de 3,8 ans (IQR 1,3&#x02013;8,4) ; 373 (27%) &#x000e9;taient VIH-positifs, 419 (30%) &#x000e9;taient VIH-n&#x000e9;gatifs et pour 602 enfants (43%) le statut &#x000e9;tait inconnu. Une TB a &#x000e9;t&#x000e9; confirm&#x000e9;e chez 84 enfants (6%); ces cas avaient plus souvent des sympt&#x000f4;mes tels que perte de poids, douleur thoracique ou contact &#x000e0; domicile avec un patient tuberculeux. L&#x02019;expectoration provoqu&#x000e9;e n&#x02019;a pas entra&#x000ee;n&#x000e9; de complications graves ni pendant ni apr&#x000e8;s sa r&#x000e9;alisation; seulement 0,8% des enfants se sont plaints de complications minimes.</p></sec><sec id="S10"><title>CONCLUSION:</title><p id="P10">Au Botswana, la expectoration provoqu&#x000e9;e p&#x000e9;diatrique s&#x02019;est av&#x000e9;r&#x000e9;e faisable et s&#x000fb;re et a contribu&#x000e9; &#x000e0; la confirmation bact&#x000e9;riologique d&#x02019;un sous-groupe d&#x02019;enfants trait&#x000e9;s pour TB.</p></sec></trans-abstract><trans-abstract xml:lang="es"><title>R&#x000c9;SUM&#x000c9;</title><sec id="S11"><title>MARCO DE REFERENCIA:</title><p id="P11">Cuatro hospitales p&#x000fa;blicos en Botswana, un pa&#x000ed;s con alta carga de morbilidad por tuberculosis (TB).</p></sec><sec id="S12"><title>OBJETIVOS:</title><p id="P12">Evaluar la factibilidad y la utilidad de la inducci&#x000f3;n del esputo en el diagn&#x000f3;stico de la TB en los ni&#x000f1;os.</p></sec><sec id="S13"><title>M&#x000c9;TODOS:</title><p id="P13">Del 2008 al 2010 se practic&#x000f3; la inducci&#x000f3;n del esputo en los ni&#x000f1;os de &#x0003c;18 a&#x000f1;os de edad remitidos por presunci&#x000f3;n diagn&#x000f3;stica de TB pulmonar. Se defini&#x000f3; la TB confirmada como la presencia como m&#x000ed;nimo de uno de los signos y s&#x000ed;ntomas indicativos de TB y un cultivo po sitivo de <italic>Mycobacterium tuberculosis.</italic> Se recogi&#x000f3; informaci&#x000f3;n sobre los s&#x000ed;ntomas asociados de la TB (tos, astenia, sudoraci&#x000f3;n nocturna, p&#x000e9;rdida del apetito, dolor tor&#x000e1;cico, p&#x000e9;rdida de peso, hemoptisis y contacto con un paciente tuberculoso) en los siguientes tres grupos de riesgo: ni&#x000f1;os positivos frente al virus de la inmunodeficiencia humana (VIH), ni&#x000f1;os negativos al VIH de &#x0003c;3 a&#x000f1;os de edad y ni&#x000f1;os negativos al VIH de &#x02a7e;3 a&#x000f1;os de edad.</p></sec><sec id="S14"><title>RESULTADOS:</title><p id="P14">Se practic&#x000f3; la inducci&#x000f3;n del esputo en 1394 ni&#x000f1;os. La mediana de la edad fue 3,8 a&#x000f1;os (IQR 1,3&#x02013;8,4), 373 fueron positivos al VIH (27%), 419 negativos al VIH (30%) y en 602 se desconoc&#x000ed;a su situaci&#x000f3;n frente al virus (43%). Se estableci&#x000f3; el diagn&#x000f3;stico de TB confirmada en 84 ni&#x000f1;os (6,0%); fue m&#x000e1;s probable que los casos confirmados presentaran p&#x000e9;rdida de peso, dolor tor&#x000e1;cico y contactos tuberculosos en el hogar. No se observaron complicaciones graves atribuibles a la inducci&#x000f3;n del esputo durante el procedimiento ni despu&#x000e9;s del mismo; solo 0,8% de los ni&#x000f1;os (9/1174) refirieron complicaciones menores.</p></sec><sec id="S15"><title>CONCLUSI&#x000d3;N:</title><p id="P15">Se demostr&#x000f3; que en Botswana la inducci&#x000f3;n del esputo es factible y segura y el procedimiento contribuy&#x000f3; a la confirmaci&#x000f3;n bacteriol&#x000f3;gica en un subgrupo de ni&#x000f1;os tratados por TB.</p></sec></trans-abstract><kwd-group><kwd>paediatrics</kwd><kwd>sputum induction</kwd><kwd>TB</kwd><kwd>diagnosis</kwd><kwd>Botswana</kwd></kwd-group></article-meta></front><body><p id="P16">ALTHOUGH paediatric cases comprise up to 20% of tuberculosis (TB) notifications in developing countries, children are often neglected in health system responses to TB.<sup><xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R4" ref-type="bibr">4</xref></sup> The burden of TB disease among children is estimated at 490 000 cases and 64 000 deaths per year.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> However, paediatric statistics may substantially underestimate the true incidence of TB, estimated at 0.3&#x02013;1.4 million cases annually,<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup> in part due to the difficulty in diagnosing TB in children.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> The majority of paediatric TB cases are smear-negative due to the typically paucibacillary presentation in children and their inability to produce sputum on demand. Although microbiological confirmation is ideal for intrathoracic TB, TB culture facilities are often unavailable.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Most paediatric TB diagnoses are clinical, relying on practical but imperfect algorithms based on history of exposure, signs and symptoms.</p><p id="P17">Diagnosis of childhood TB is particularly challenging in human immunodeficiency virus (HIV) co-infected children.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> In Botswana, where the national prevalence of HIV is 17.6%, and 5% in children aged &#x0003c;15 years, TB incidence has nearly tripled in the last two decades.<sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref></sup> Although Botswana has the world&#x02019;s sixth highest TB notification rate (536 per 100000 population in 2008),<sup><xref rid="R9" ref-type="bibr">9</xref></sup> robust paediatric diagnostic services have historically been unavailable.</p><p id="P18">Sputum induction may increase the diagnostic yield in paediatric TB, but data from settings similar to ours are scarce.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> University-affiliated hospitals in Cape Town, South Africa, and Kampala, Uganda, have achieved culture positivity rates of up to 30%.<sup><xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup> Although a successful paediatric sputum induction programme at a primary facility in the Western Cape was recently reported,<sup><xref rid="R15" ref-type="bibr">15</xref></sup> we are unaware of published paediatric sputum induction data from smaller facilities, or from African settings other than South Africa. We report the results of a programme that introduced paediatric sputum induction to Botswana&#x02019;s public hospitals in Gaborone, Francistown, Serowe and Maun. The findings have implications for the feasibility of rolling out paediatric sputum induction in similar settings, the utility of sputum induction for microbiological diagnosis in paediatric TB suspects and the development of locally relevant diagnostic algorithms.</p><sec id="S16"><title>STUDY POPULATION AND METHODS</title><sec id="S17"><title>Study setting</title><p id="P19">The study was conducted in four large public hospitals across Botswana. Sites were chosen based on high TB incidence in surrounding catchment areas. A series of steps established each new site: first, a respiratory therapist developed a sputum induction training curriculum. At each site, hospital management was briefed on the project objectives and equipment for sputum induction, and a work space was organised. A core sputum induction team, consisting of a respiratory therapist, a nurse, a health care auxiliary and a paediatrician, hosted a 2-day workshop describing the pathophysiology of paediatric TB and provided hands-on training by conducting sputum induction among paediatric TB suspects. A local nurse was then designated to coordinate the scheduling and continued education for sputum induction in each hospital.</p></sec><sec id="S18"><title>Sputum induction technique and sample processing</title><p id="P20">After a history was taken and physical examination was performed, patients received a standard dose of salbutamol nebuliser for 3&#x02013;5 min as prophylaxis against broncho-constriction. Nebulised hypertonic saline (3&#x02013;5%) was inhaled by mask until the patient produced a wet cough (typically 5&#x02013;15 min). Suction at 20 mmHg pressure was applied through a suction catheter inserted into the nasopharynx or oropharynx if sputum was being coughed and expectorated orally until &#x0003e;2 ml of sputum was collected. Only one specimen was collected per patient, as at the time there was evidence that one induced sputum sample may have the same yield as three gastric aspirates.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Specimens were labelled, dated and stored at a temperature of 4&#x000b0;C (<xref rid="APP1" ref-type="app">Appendix</xref>).</p><p id="P21">Samples were transported at least twice weekly to the regional laboratory for acid-fast bacilli smear and to the National TB Reference Laboratory for repeat smear using concentrated fluorescence microscopy, culture and drug susceptibility testing. Samples arriving &#x0003e;1 week after collection were discarded due to concerns about bacterial contamination. Sputum specimens were decontaminated using sodium hydroxide and mucolysed with <italic>N</italic>-acetyl-L-cysteine.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Samples for culture were vortexed for 30 s, centrifuged at 3000&#x000d7; <italic>g</italic> for 15 min and inoculated onto L&#x000f6;wenstein Jensen media at 37&#x000b0;C for up to 8 weeks.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p></sec><sec id="S19"><title>Definitions</title><p id="P22">Microbial confirmation was defined as at least one positive culture with confirmed <italic>Mycobacterium tuberculosis</italic> speciation from sputum. Confirmed TB was defined as the presence of at least one sign or symptom suggestive of TB and microbiological confirmation.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Age was stratified consistent with other childhood TB studies.<sup><xref rid="R17" ref-type="bibr">17</xref>&#x02013;<xref rid="R19" ref-type="bibr">19</xref></sup></p></sec><sec id="S20"><title>Data collection</title><p id="P23">TB signs and symptoms, including HIV status, were recorded for each TB suspect. Care givers were encouraged to have children tested if HIV status was unknown and to return for the sputum induction results. If a child did not return for follow-up and was diagnosed with confirmed TB, the care givers were contacted by telephone. If this was unsuccessful, a home visit was arranged. Patient demographics, clinical characteristics and any complications were captured in a standardised form. Information was entered into a secure electronic database.</p></sec><sec id="S21"><title>Analysis</title><p id="P24">We assessed the diagnostic sensitivity and specificity of signs, symptoms and demographic variables.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> To explore information on TB-associated symptoms,<sup><xref rid="R19" ref-type="bibr">19</xref></sup> we carried out logistic regression and classification and regression trees, with bagging<sup><xref rid="R20" ref-type="bibr">20</xref></sup> to address imbalances in outcome class distributions. For the purposes of analysis, we considered the outcome in three risk groups: HIV-infected children (all ages), non-HIV-infected children aged &#x0003c;3 years and non-HIVinfected children aged &#x0003e;3 years.</p><p id="P25">Statistical comparisons were performed using &#x003c7;<sup>2</sup> test, Fisher&#x02019;s exact or the Wilcoxon rank-sum test as appropriate. Analyses used Stata Statistical Software: Release 12 (Stata Corp, College Station, TX, USA) and <italic>R</italic> version 2.14 (R Foundation for Statistical Computing, Vienna, Austria; <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org</ext-link>). Findings were considered statistically significant when <italic>P</italic> &#x0003c; 0.05.</p></sec><sec id="S22"><title>Ethics</title><p id="P26">Approval was granted by the Botswana Ministry of Health, the Princess Marina Hospital, the Nyangabgwe Referral Hospital, Gaborone, Botswana, the US Centers for Diseases Control and Prevention, At lanta, GA, USA, the Baylor College of Medicine, Houston, TX, USA, and the University of Pennsylvania, Philadelphia, PA, USA.</p></sec></sec><sec id="S23"><title>RESULTS</title><p id="P27">Following the successful rollout of sputum induction in Botswana, 2007 subjects were referred for the procedure; 1394 (69%) were eligible for analysis (<xref rid="F1" ref-type="fig">Figure 1</xref>). Of these, 84 (6%) were diagnosed with confirmed TB. Study subjects did not differ by demographic or HIV status; however, culture-positive TB was more common among older children (<xref rid="T1" ref-type="table">Table 1</xref>).</p><p id="P28"><xref rid="T2" ref-type="table">Table 2</xref> shows signs and symptoms. Confirmed TB was associated with each of the following: weight loss, chest pain, household TB suspect and household TB contacts. <xref rid="T3" ref-type="table">Table 3</xref> indicates the value of individual variables used to diagnose confirmed TB within the relevant risk groups. Although fever for &#x0003e;14 days trended towards higher sensitivity in the HIV-infected group than in the HIV-negative group, this failed to reach statistical significance. Similarly, fatigue and chest pain appeared more sensitive in the HIV-infected than the HIV-negative group, but did not reach statistical significance. Multivariate modelling using parametric and non-parametric approaches failed to identify any variables significantly associated with confirmed TB.</p><p id="P29">The procedure was contra-indicated in 1.5% (20/1294) of patients due to wheeze (<italic>n</italic> = 16, 80%), severe respiratory distress (<italic>n</italic> = 2, 10%), thrombocytopaenia (<italic>n</italic> = 1, 5%) and epistaxis (<italic>n</italic> = 1, 5%). Adverse events data were captured in 84% (1174/1394) of the patients (<xref rid="T4" ref-type="table">Table 4</xref>); there were no serious events and only 9/1174 (0.8%) patients had minor events. <xref rid="T5" ref-type="table">Table 5</xref> summarises the clinical features of children for whom mycobacteria other than tuberculosis were cultured; outcomes were unknown.</p></sec><sec id="S24"><title>DISCUSSION</title><p id="P30">Sputum induction as a modality for TB diagnosis in children was successfully introduced in four Botswana hospitals in this first phase of a national scale-up. Previous sputum induction projects in resourcec onstrained settings have examined the efficacy of the procedure at tertiary academic institutions or in clinical trials.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> This project, however, focused on implementing sputum induction in national health care facilities, including non-academic settings.</p><p id="P31">Previous studies from resource-constrained settings have shown variable diagnostic yield of TB in children and a number of these focused on hospitalised children.<sup><xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup> Hatherill et al. compared the diagnostic yield of TB from sputum induction and gastric lavage among children in an out-patient community setting, where the crude diagnostic yield for sputum induction was 5.8% compared to 6.2% for gastric lavage.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> A Ugandan in-patient study of sputum induction yielded 12% positive smears and 30% positive cultures for <italic>M. tuberculosis</italic>.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> Zar et al. showed a 9% yield with sputum induction compared to a 6% yield from gastric lavage in in-patients.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> In comparison, our sputum induction yield of 6% was comparable to those of community-based studies,<sup><xref rid="R21" ref-type="bibr">21</xref></sup> and lower than in studies focusing on hospitalised children.<sup><xref rid="R11" ref-type="bibr">11</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup></p><p id="P32">We found no significant differences in TB yield between in-patient and out-patient groups. Compared to our cohort, Zar et al.&#x02019;s hospitalised child cohort were of similar age but were likely more ill, with 38% HIV-infected and 27% requiring supplemental oxygen.<sup><xref rid="R11" ref-type="bibr">11</xref></sup>Hospitalised children who are more ill in such settings are likely to have more severe TB disease and hence a higher diagnostic yield from sputum induction.</p><p id="P33">We found that symptom-based screening using weight loss, fever, household TB contact or suspect and chest pain correlated with confirmed TB. The sensitivity of cough as a diagnostic symptom remained low across the various risk groups. Hatherill et al. found an association between confirmed TB and cough of &#x0003e;2 weeks or weight loss, but none with household TB contacts.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p><p id="P34">History of a household contact had a sensitivity of 59% for confirmed TB in high-risk children who were non-HIV-infected and aged &#x0003c;3 years. As relatively few children with household TB exposure will be missed on symptom-based clinical screening, a positive household TB contact should be incorporated into national TB diagnostic algorithms. For TB household contacts, Marais et al. reported a lower sensitivity across all risk groups and lower sensitivity (69%) and specificity (54%) among non-HIV-infected children aged &#x0003c;3 years.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> While TB-HIV prevalence was high in both Marais et al.&#x02019;s study and ours, our study represents a larger cohort in a setting with more extensive highly active antiretroviral therapy coverage (93% in Botswana vs. 55% in South Africa in 2010).<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p><p id="P35">This study has some limitations. This analysis of retrospective data limits conclusions to a documented patient population; those referred may not represent all patients presenting to facilities. Although we used a standardised data collection form, the completeness of the data presented here may be higher than what would be captured under operational conditions. Our diagnostic yield of 6% was low, probably due to the low diagnostic yield seen in children generally,<sup><xref rid="R1" ref-type="bibr">1</xref>&#x02013;<xref rid="R4" ref-type="bibr">4</xref></sup> the low pre-test probability of many who were referred and the fact that sputum induction was performed only once for each subject. Refining the clinical criteria to better target future sputum induction procedures may reduce programme costs.</p><p id="P36">Programme challenges included lost sputum samples, contaminated sputum cultures and unavailable culture results. As a result of high staff turnover, there were continuously new health care workers requiring training in sputum induction. As children were often referred by their primary doctor, accessing accurate clinical and radiological data was often a challenge, as was post-sputum induction clinical outcome follow-up. Due to low HIV testing coverage, 43% of those in our cohort had unknown HIV status. Furthermore, we did not assess for extra-pulmonary TB disease and we were unable to differentiate common intra-thoracic disease entities and their associated symptoms or yields, as accurate radiological data were not routinely available. Finally, our definition of a TB case required microbiological confirmation, which is achievable in only 30&#x02013;50% of children with pulmonary TB, which may have concealed actual clinical information from identification in our multivariate analyses.</p></sec><sec id="S25"><title>CONCLUSION</title><p id="P37">Sputum induction can be performed successfully at referral and secondary hospitals in Botswana and has potential for further rollout in Botswana and similar settings. Findings from this multi-site implementation project suggest that sputum induction should preferentially be performed on children who meet a number of clinical and demographic criteria for TB. To improve the method towards better yield and costeffectiveness, future studies should consider prediction modelling using TB outcomes informed by both confirmed and carefully selected empirical diagnoses. Future studies should explore the optimal timing and number of samples needed, and elucidate whether samples should be collected using a combination of available techniques (e.g., sputum induction and gastric aspirate).</p></sec></body><back><ack id="S26"><title>Acknowledgements</title><p id="P38">The authors thank all nursing staff, doctors, health care auxiliaries, laboratory staff and the management at the Baylor College of Medicine and the Botswana&#x02013;Baylor Children&#x02019;s Clinical Centre of Excellence, Gaborone, Botswana, and all participating institutions for supporting this project. They also thank the children and their parents for participating in the project. This publication was made possible through core services and support from the Penn Center for AIDS Research, a National Institutes for Health funded programme (P30 AI 045008). The sputum induction project was supported by the US President&#x02019;s Emergency Plan for AIDS Relief grant cooperative agreement number 1U2G/PS001881&#x02013;03 through the US Centre for Disease Control&#x02013;Botswana.</p><p id="P39">The views and opinions expressed in the article are solely those of the authors and do not necessarily reflect those of the US Agency for International Development nor those of the US Government.</p></ack><fn-group><fn fn-type="COI-statement" id="FN1"><p id="P100">Conflict of interest: none declared.</p></fn><fn id="FN2"><label>*</label><p id="P101">Some ultrasonic nebulisers have a loading volume and should not run dry. If it does run dry, a safety mechanism will shut the machine off.</p></fn></fn-group><app-group><app id="APP1"><title>APPENDIX</title><sec id="S27"><title>Sputum induction in children</title><p id="P40">Precaution: Only health care workers (HCWs) who have been trained in proper, safe techniques should perform sputum induction.</p><list list-type="bullet" id="L1"><list-item><p id="P41">Patients should be under observation at all times during sputum induction</p></list-item><list-item><p id="P42">Sputum induction should <underline>not</underline> be performed in children with:
<list list-type="simple" id="L2"><list-item><p id="P43">&#x02014;Acute (active) asthma</p></list-item><list-item><p id="P44">&#x02014;Any signs of moderate to severe respiratory distress</p></list-item><list-item><p id="P45">&#x02014;Wheezing</p></list-item><list-item><p id="P46">&#x02014;Abnormal vital signs</p></list-item><list-item><p id="P47">&#x02014;Epistaxis</p></list-item><list-item><p id="P48">&#x02014;Pneumothorax</p></list-item><list-item><p id="P49">&#x02014;Fractured ribs or other chest trauma</p></list-item><list-item><p id="P50">&#x02014;Recent eye surgery</p></list-item></list></p></list-item></list></sec><sec id="S28"><title>Infection control</title><p id="P51">As sputum induction produces coughing, it is likely that infectious droplets, if present, will be expelled into the air. Sputum induction should therefore be performed in a well-ventilated area.</p><list list-type="bullet" id="L3"><list-item><p id="P52">The HCW should wear an N95 respirator throughout the procedure and disposable gloves when handling sputum.</p></list-item><list-item><p id="P53">If outside, determine the wind direction before beginning the procedure. The patient must always be located downwind of the HCW.</p></list-item><list-item><p id="P54">If inside, open doors and windows and use fans to direct airflow away from the HCW.</p></list-item><list-item><p id="P55">Nebulisers and tubing should be sterilised after every use (with precept or glutaraldehyde) for 15&#x02013;20 min.</p></list-item></list></sec><sec id="S29"><title>Preparations for the procedure: pre-operative fasting requirements</title><list list-type="bullet" id="L4"><list-item><p id="P56">The child should have fasted for 6 h before the procedure.</p></list-item><list-item><p id="P57">Do not perform sputum induction if the child has eaten within 3 h before the procedure. Medication with a small amount of liquid is acceptable.</p></list-item></list></sec><sec id="S30"><title>Procedure preparations: area setup</title><list list-type="bullet" id="L5"><list-item><p id="P58">Set up area ahead of time to minimise the anxiety level of the child.</p></list-item><list-item><p id="P59">Keep syringes and needles out of sight.</p></list-item><list-item><p id="P60">Preload the equipment with salbutamol and normal saline.</p></list-item><list-item><p id="P61">Keep a suction catheter or Yankaeur nearby in case of vomiting.</p></list-item><list-item><p id="P62">Fill out laboratory request forms.</p></list-item></list></sec><sec id="S31"><title>Procedure preparation: patient positioning</title><list list-type="bullet" id="L6"><list-item><p id="P63">Have the care giver hold the child during the procedure. If this is not possible, an assistant should hold the child.</p></list-item><list-item><p id="P64">Position the child in the upright or semi-upright position.</p></list-item><list-item><p id="P65">Hold infants supine in the feeding position.</p></list-item><list-item><p id="P66">Stand or sit where you can clearly observe the child and all of the equipment.</p></list-item></list></sec><sec id="S32"><title>Procedure</title><list list-type="bullet" id="L7"><list-item><p id="P67">Run correct dosage of salbutamol in normal saline (0.9% sodium chloride [NaCl] solution) for 3&#x02013;5 min.</p></list-item><list-item><p id="P68">Add hypertonic saline (3&#x02013;5% NaCl solution) to the solution.</p></list-item><list-item><p id="P69">Continue nebulisation for at least 10 min.
<list list-type="simple" id="L8"><list-item><p id="P70">&#x02014;If the child coughs during this time and produces a specimen, the procedure is completed.</p></list-item><list-item><p id="P71">&#x02014;If the child does not produce a specimen within 10 min, insert the suction catheter, nasopharyngeal airway, or oropharyngeal airway to stimulate a cough.</p></list-item></list></p></list-item><list-item><p id="P72">When there is adequate sputum in the oronasopharyngeal area, insert the catheter from the sputum trap (either alone or through an airway).</p></list-item><list-item><p id="P73">Apply vacuum until at least 2 ml of sputum is collected in the sputum trap. Start at 15&#x02013;20 kPa pressure and increase only if needed.</p></list-item><list-item><p id="P74">Ensure that the sputum collection container is tightly sealed and labelled.</p></list-item></list></sec><sec id="S33"><title>After the procedure</title><list list-type="bullet" id="L9"><list-item><p id="P75">Monitor the child for several minutes. If pulse oximetry is below baseline or there are signs of respiratory distress, give oxygen and suction excess sputum from the airway.</p></list-item><list-item><p id="P76">Educate the care giver that coughing may be more frequent within 24 h of the procedure.</p></list-item><list-item><p id="P77">Send samples immediately to the laboratory. Refrigerate all samples that are sent for culture.</p></list-item><list-item><p id="P78">Keep samples out of direct sunlight.</p></list-item></list></sec><sec id="S34"><title>Stop the procedure if the child has any of the following:</title><list list-type="bullet" id="L10"><list-item><p id="P79">Respiratory distress, including increased respiratory rate, wheezing, laboured breathing, chest wall</p></list-item><list-item><p id="P80">retractions, nasal fl aring or cyanosis</p></list-item><list-item><p id="P81">Profuse sweating</p></list-item><list-item><p id="P82">Nausea or vomiting</p></list-item><list-item><p id="P83">Light-headedness, dizziness or loss of consciousness</p></list-item></list></sec><sec id="S35"><title>Equipment required:</title><list list-type="bullet" id="L11"><list-item><p id="P84">N95 respirator for the HCW</p></list-item><list-item><p id="P85">Ultrasonic nebuliser machine<xref ref-type="fn" rid="FN2">*</xref></p></list-item><list-item><p id="P86">Sterile hypertonic saline (3&#x02013;5%)</p></list-item><list-item><p id="P87">Salbutamol and 0.9% NaCl solution (normal saline)</p></list-item><list-item><p id="P88">Suction machine and catheter or Yankaeur</p></list-item><list-item><p id="P89">Pulse oximetry machine</p></list-item><list-item><p id="P90">Oxygen cylinder</p></list-item><list-item><p id="P91">Goggles</p></list-item><list-item><p id="P92">Small volume nebuliser</p></list-item><list-item><p id="P93">The compressor</p></list-item><list-item><p id="P94">Infra-red light</p></list-item><list-item><p id="P95">Sputum traps</p></list-item><list-item><p id="P96">Disinfectant (precept or glutaraldehyde)</p></list-item><list-item><p id="P97">Disposable gloves</p></list-item><list-item><p id="P98">Completed laboratory request form with patient details</p></list-item><list-item><p id="P99">Sterile sputum collection container identified with the patient details</p></list-item></list></sec></app></app-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><name><surname>Keshavjee</surname><given-names>S</given-names></name>, <name><surname>Harrington</surname><given-names>M</given-names></name>, <name><surname>Gonsalves</surname><given-names>G</given-names></name>, <name><surname>Chesire</surname><given-names>L</given-names></name>, <name><surname>Farmer</surname><given-names>PE</given-names></name>. <article-title>Time for zero deaths from tuberculosis</article-title>. <source>Lancet</source>
<year>2011</year>; <volume>378</volume>: <fpage>1449</fpage>&#x02013;<lpage>1450</lpage>.<pub-id pub-id-type="pmid">22018005</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><name><surname>Nelson</surname><given-names>LJ</given-names></name>, <name><surname>Wells</surname><given-names>CD</given-names></name>. <article-title>Global epidemiology of childhood tu-berculosis</article-title>. <source>Int J Tuberc Lung Dis</source>
<year>2004</year>; <volume>8</volume>: <fpage>636</fpage>&#x02013;<lpage>647</lpage>.<pub-id pub-id-type="pmid">15137548</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><name><surname>Marais</surname><given-names>BJ</given-names></name>, <name><surname>Schaaf</surname><given-names>HS</given-names></name>. <article-title>Childhood tuberculosis: an emerging and previously neglected problem</article-title>. <source>Infect Dis Clin North Am</source>
<year>2010</year>; <volume>24</volume>: <fpage>727</fpage>&#x02013;<lpage>749</lpage>.<pub-id pub-id-type="pmid">20674801</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><name><surname>du Cros</surname><given-names>P</given-names></name>, <name><surname>Nyang&#x02019;wa</surname><given-names>B</given-names></name>, <name><surname>Gale</surname><given-names>M</given-names></name>, <etal/>
<article-title>Counting children: com-paring reporting for paediatric HIV and tuberculosis</article-title>. <source>Bull World Health Organ</source>
<year>2011</year>; <volume>89</volume>: <fpage>855</fpage>.<pub-id pub-id-type="pmid">22271937</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <source>Global tuberculosis report, 2012</source>. <comment>WHO/HTM/TB/2012.6.</comment>
<publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>, <year>2012</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/publications/global_report/gtbr12_main.pdf">http://www.who.int/tb/publications/global_report/gtbr12_main.pdf</ext-link> Accessed January 2014.</comment></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><name><surname>Graham</surname><given-names>SM</given-names></name>, <name><surname>Ahmed</surname><given-names>T</given-names></name>, <name><surname>Amanulla</surname><given-names>F</given-names></name>, <etal/>
<article-title>Evaluation of tuber-culosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel</article-title>. <source>J Infect Dis</source>
<year>2012</year>; <volume>205</volume> (<issue>Suppl 2</issue>): <fpage>S199</fpage>&#x02013;<lpage>S208</lpage>.<pub-id pub-id-type="pmid">22448023</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><name><surname>Edwards</surname><given-names>DJ</given-names></name>, <name><surname>Kitetele</surname><given-names>F</given-names></name>, <name><surname>Van Rie</surname><given-names>A</given-names></name>. <article-title>Agreement between clinical scoring systems used for the diagnosis of pediatric tuberculosis in the HIV era</article-title>. <source>Int J Tuberc Lung Dis</source>
<year>2007</year>; <volume>11</volume>: <fpage>263</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">17352090</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="book"><collab>Central Statistics Office, Ministry of Health Botswana</collab>. <source>The 2008 Botswana AIDS Impact Survey III (BAIS III)</source>. <publisher-loc>Gaborone, Botswana</publisher-loc>: <publisher-name>MoH</publisher-name>, <year>2008</year>.</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="book"><collab>Botswana National Tuberculosis Programme</collab>. <source>Annual tubercu-losis and leprosy report, 2006&#x02013;2008</source>. <publisher-loc>Gaborone, Botswana</publisher-loc>: <publisher-name>Ministry of Health, Republic of Botswana</publisher-name>, <year>2010</year>.</mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><name><surname>Zar</surname><given-names>HJ</given-names></name>, <name><surname>Connell</surname><given-names>TG</given-names></name>, <name><surname>Nicol</surname><given-names>M</given-names></name>. <article-title>Diagnosis of pulmonary tuber-culosis in children: new advances</article-title>. <source>Expert Rev Anti Infect Ther</source>
<year>2010</year>; <volume>8</volume>: <fpage>277</fpage>&#x02013;<lpage>288</lpage>.<pub-id pub-id-type="pmid">20192682</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><name><surname>Zar</surname><given-names>HJ</given-names></name>, <name><surname>Hanslo</surname><given-names>D</given-names></name>, <name><surname>Apolles</surname><given-names>P</given-names></name>, <name><surname>Swingler</surname><given-names>G</given-names></name>, <name><surname>Hussey</surname><given-names>G</given-names></name>. <article-title>Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study</article-title>. <source>Lancet</source>
<year>2005</year>; <volume>365</volume>: <fpage>130</fpage>.<pub-id pub-id-type="pmid">15639294</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><name><surname>Zar</surname><given-names>HJ</given-names></name>, <name><surname>Tannebaum</surname><given-names>E</given-names></name>, <name><surname>Hanslo</surname><given-names>D</given-names></name>, <name><surname>Hussey</surname><given-names>G</given-names></name>. <article-title>Sputum induc-tion as a diagnostic tool for community-acquired pneumonia in infants and young children from a high HIV prevalence area</article-title>. <source>Pediatr Pulmonol</source>
<year>2003</year>; <volume>36</volume>: <fpage>58</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">12772225</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><name><surname>Iriso</surname><given-names>R</given-names></name>, <name><surname>Mudido</surname><given-names>PM</given-names></name>, <name><surname>Karamagi</surname><given-names>C</given-names></name>, <name><surname>Whalen</surname><given-names>C</given-names></name>. <article-title>The diagnosis of childhood tuberculosis in an HIV-endemic setting and the use of induced sputum</article-title>. <source>Int J Tuberc Lung Dis</source>
<year>2005</year>; <volume>9</volume>: <fpage>716</fpage>&#x02013;<lpage>726</lpage>.<pub-id pub-id-type="pmid">16013765</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><name><surname>Qureshi</surname><given-names>UA</given-names></name>, <name><surname>Gupta</surname><given-names>AK</given-names></name>, <name><surname>Mahajan</surname><given-names>B</given-names></name>, <etal/>
<article-title>Microbiological diagnosis of pulmonary tuberculosis in children: comparative study of induced sputum and gastric lavage</article-title>. <source>Indian J Pediatr</source>
<year>2011</year>; <volume>78</volume>: <fpage>1429</fpage>&#x02013;<lpage>1430</lpage>.<pub-id pub-id-type="pmid">21614605</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>HA</given-names></name>, <name><surname>Apolles</surname><given-names>P</given-names></name>, <name><surname>de Villiers</surname><given-names>PJT</given-names></name>, <name><surname>Zar</surname><given-names>HJ</given-names></name>. <article-title>Sputum induction for microbiological diagnosis of childhood pulmonary tuberculosis in a community setting</article-title>. <source>Int J Tuberc Lung Dis</source>
<year>2011</year>; <volume>15</volume>: <fpage>1185</fpage>&#x02013;<lpage>1190</lpage>.<pub-id pub-id-type="pmid">21943843</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><collab>American Thoracic Society/Centers for Disease Control and Prevention</collab>. <article-title>Diagnostic standards and classification of tuberculosis in adults and children</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2000</year>; <volume>161</volume>: <fpage>1376</fpage>&#x02013;<lpage>1395</lpage>.<pub-id pub-id-type="pmid">10764337</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><name><surname>Marais</surname><given-names>BJ</given-names></name>, <name><surname>Donald</surname><given-names>PR</given-names></name>, <name><surname>Gie</surname><given-names>RP</given-names></name>, <name><surname>Schaaf</surname><given-names>HS</given-names></name>, <name><surname>Beyers</surname><given-names>N</given-names></name>. <article-title>Diver-sity of disease in childhood pulmonary tuberculosis</article-title>. <source>Ann Trop Paed</source>
<year>2005</year>; <volume>25</volume>: <fpage>79</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><name><surname>Marais</surname><given-names>BJ</given-names></name>, <name><surname>Gie</surname><given-names>RP</given-names></name>, <name><surname>Schaaf</surname><given-names>HS</given-names></name>, <name><surname>Hesseling</surname><given-names>AC</given-names></name>, <name><surname>Enarson</surname><given-names>DA</given-names></name>, <name><surname>Beyers</surname><given-names>N</given-names></name>. <article-title>The spectrum of disease in children treated for tuberculosis in a highly endemic area</article-title>. <source>Int J Tuberc Lung Dis</source>
<year>2006</year>; <volume>10</volume>: <fpage>732</fpage>&#x02013;<lpage>738</lpage>.<pub-id pub-id-type="pmid">16848333</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><name><surname>Marais</surname><given-names>BJ</given-names></name>, <name><surname>Gie</surname><given-names>RP</given-names></name>, <name><surname>Hesseling</surname><given-names>AC</given-names></name>, <etal/>
<article-title>A refined symptom-based approach to diagnose pulmonary tuberculosis in children</article-title>. <source>Pediatrics</source>
<year>2006</year>; <volume>118</volume>: <fpage>e1350</fpage>&#x02013;<lpage>1359</lpage>.<pub-id pub-id-type="pmid">17079536</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><name><surname>Breiman</surname><given-names>L</given-names></name>
<article-title>Bagging predictors</article-title>. <source>Machine Learning</source>
<year>1996</year>; <volume>24</volume>: <fpage>123</fpage>&#x02013;<lpage>140</lpage>.</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Hawkridge</surname><given-names>T</given-names></name>, <name><surname>Zar</surname><given-names>HJ</given-names></name>, <etal/>
<article-title>Induced sputum or gastric lavage for community based diagnosis of childhood pulmonary tuberculosis?</article-title>
<source>Arch Dis Child</source>
<year>2009</year>; <volume>94</volume>: <fpage>195</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">18829621</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="book"><collab>World Health Organization/Joint United Nations Programme on HIV/AIDS/United Nations International Childrens&#x02019; Emergency Fund</collab>. <source>Global HIV/AIDS response</source>. <publisher-loc>Annex 4. Geneva, Switzerland</publisher-loc>: <publisher-name>WHO</publisher-name>, <year>2011</year>
<comment><ext-link ext-link-type="uri" xlink:href="http://www.who.int/hiv/data/en/">http://www.who.int/hiv/data/en/</ext-link> Accessed December 2013.</comment></mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p id="P102">Flow diagram of all children evaluated for TB. * Subjects were referred due to suspicion of pulmonary TB; referral was at the discretion of a primary health care nurse or doctor. <sup>&#x02020;</sup> Children for whom MOTT were cultured as the sole organism (in one or more cultures) were classified as MOTT. Children who grew <italic>M. tuberculosis</italic> from one culture and MOTT from another were classified as TB. <sup>&#x02021;</sup> Subjects were included in the study cohort if at least one culture result was available and uncontaminated. An unavailable result meant that there was no laboratory report even when a sample was taken from the patient and sent to the laboratory. This may have been due to the fact that cultures were not performed or, if performed, the results were not recorded or reported to the clinicians. <sup>&#x000a7;</sup> Microbiological confirmation defined as positive for TB using culture. MOTT = mycobacteria other than TB; TB = tuberculosis.</p></caption><graphic xlink:href="nihms-991654-f0001"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p id="P103">Demographics of children who underwent sputum induction in Botswana by TB status</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="top" rowspan="1">Cohort by microbiological status<xref rid="TFN1" ref-type="table-fn">*</xref><sup><xref rid="TFN2" ref-type="table-fn">&#x02020;</xref></sup><hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Variable</th><th align="center" valign="top" rowspan="1" colspan="1">Total cohort (<italic>n</italic> = 1394) <italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1">AFB-positive (<italic>n</italic> = 47) <italic>n</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1">TB culture-positive (<italic>n</italic> = 84) <italic>n</italic> (%)</th></tr></thead><tbody><tr><td colspan="4" align="left" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td align="center" valign="top" rowspan="1" colspan="1">651 (47)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">41 (6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td align="center" valign="top" rowspan="1" colspan="1">743 (53)</td><td align="center" valign="top" rowspan="1" colspan="1">24 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">43 (6)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">Age, years</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">3.8 [1.3&#x02013;8.4]</td><td align="center" valign="top" rowspan="1" colspan="1">5.9 [1.3&#x02013;11.2]</td><td align="center" valign="top" rowspan="1" colspan="1">5.9 [2.1&#x02013;10.1]</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;3</td><td align="center" valign="top" rowspan="1" colspan="1">613 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3&#x02013;4</td><td align="center" valign="top" rowspan="1" colspan="1">173 (12)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">11 (6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;5&#x02013;9</td><td align="center" valign="top" rowspan="1" colspan="1">320 (23)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">23 (7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;10&#x02013;17</td><td align="center" valign="top" rowspan="1" colspan="1">252 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">16 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">21 (8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">36 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">3 (8)</td></tr><tr><td colspan="4" align="left" valign="top" rowspan="1">HIV status</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td align="center" valign="top" rowspan="1" colspan="1">373 (27)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Negative</td><td align="center" valign="top" rowspan="1" colspan="1">419 (30)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">28 (7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unknown</td><td align="center" valign="top" rowspan="1" colspan="1">602 (43)</td><td align="center" valign="top" rowspan="1" colspan="1">19 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">34 (6)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>*</label><p id="P104">Data for each variable were not captured for all subjects. Proportion calculated as total positive by the diagnostic modality with the characteristic/total number with the characteristic for whom the diagnostic modality was captured (%).</p></fn><fn id="TFN2"><label>&#x02020;</label><p id="P105">47/1394 (3%) were AFB-positive, 84/1394 (6%) were TB culture-positive. TB = tuberculosis; AFB = acid-fast bacilli; IQR = interquartile range; HIV = human immunodeficiency virus.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2</label><caption><p id="P106">TB symptoms and signs of 1394 children who underwent sputum induction by TB status</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="2" align="center" valign="top" colspan="1"/><th rowspan="2" align="center" valign="bottom" colspan="1">Proportion among those with variable captured<xref rid="TFN3" ref-type="table-fn">*</xref>
<italic>n/N</italic> (%)</th><th colspan="2" align="center" valign="bottom" rowspan="1">TB diagnostic modality<xref rid="TFN3" ref-type="table-fn">*</xref><hr/></th><th colspan="3" align="center" valign="bottom" rowspan="1">Positive microbiological TB status<sup><xref rid="TFN4" ref-type="table-fn">&#x02020;</xref></sup><hr/></th></tr><tr><th align="center" valign="top" rowspan="1" colspan="1">AFB-positive<sup><xref rid="TFN5" ref-type="table-fn">&#x02021;</xref></sup> (<italic>n</italic> = 47) <italic>n/N</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1">TB culturepositive<sup><xref rid="TFN4" ref-type="table-fn">&#x02020;</xref></sup> (<italic>n</italic> = 84) <italic>n/N</italic> (%)</th><th align="center" valign="top" rowspan="1" colspan="1">Those without symptom</th><th align="center" valign="top" rowspan="1" colspan="1">Those with symptom</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Symptom</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Weight loss</td><td align="center" valign="top" rowspan="1" colspan="1">678/1264 (54)</td><td align="center" valign="top" rowspan="1" colspan="1">25/44 (57)</td><td align="center" valign="top" rowspan="1" colspan="1">50/73 (68)</td><td align="center" valign="top" rowspan="1" colspan="1">23/586 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">50/678 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cough &#x0003e;14 days</td><td align="center" valign="top" rowspan="1" colspan="1">1052/1355 (78)</td><td align="center" valign="top" rowspan="1" colspan="1">35/46 (76)</td><td align="center" valign="top" rowspan="1" colspan="1">65/79 (82)</td><td align="center" valign="top" rowspan="1" colspan="1">14/303 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">65/1052 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fever &#x0003e;14 days</td><td align="center" valign="top" rowspan="1" colspan="1">540/1339 (40)</td><td align="center" valign="top" rowspan="1" colspan="1">24/46 (52)</td><td align="center" valign="top" rowspan="1" colspan="1">41/81 (51)</td><td align="center" valign="top" rowspan="1" colspan="1">40/799 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">41/540 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Night sweats &#x0003e;14 days</td><td align="center" valign="top" rowspan="1" colspan="1">581/1328 (44)</td><td align="center" valign="top" rowspan="1" colspan="1">22/45 (49)</td><td align="center" valign="top" rowspan="1" colspan="1">42/78 (54)</td><td align="center" valign="top" rowspan="1" colspan="1">36/747 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">42/581 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.06</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fatigue &#x0003e;14 days</td><td align="center" valign="top" rowspan="1" colspan="1">380/1324 (29)</td><td align="center" valign="top" rowspan="1" colspan="1">21/46 (46)</td><td align="center" valign="top" rowspan="1" colspan="1">24/77 (31)</td><td align="center" valign="top" rowspan="1" colspan="1">53/944 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">24/380 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Poor appetite &#x0003e;14 days</td><td align="center" valign="top" rowspan="1" colspan="1">458/1349 (34)</td><td align="center" valign="top" rowspan="1" colspan="1">22/46 (48)</td><td align="center" valign="top" rowspan="1" colspan="1">31/80 (39)</td><td align="center" valign="top" rowspan="1" colspan="1">49/891 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">31/458 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Chest pain &#x0003e;14 days<sup><xref rid="TFN6" ref-type="table-fn">&#x000a7;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">229/1014 (23)</td><td align="center" valign="top" rowspan="1" colspan="1">10/32 (31)</td><td align="center" valign="top" rowspan="1" colspan="1">29/59 (41)</td><td align="center" valign="top" rowspan="1" colspan="1">19/361 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">18/143 (13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Haemoptysis</td><td align="center" valign="top" rowspan="1" colspan="1">35/1260 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">1/43 (2)</td><td align="center" valign="top" rowspan="1" colspan="1">1/76 (1)</td><td align="center" valign="top" rowspan="1" colspan="1">75/1225(6)</td><td align="center" valign="top" rowspan="1" colspan="1">1/35 (3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medications</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Recent antibiotics<sup><xref rid="TFN7" ref-type="table-fn">&#x000b6;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">497/1258 (40)</td><td align="center" valign="top" rowspan="1" colspan="1">18/44 (41)</td><td align="center" valign="top" rowspan="1" colspan="1">35/75 (47)</td><td align="center" valign="top" rowspan="1" colspan="1">40/761 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">35/497 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Previously on anti-tuberculosis treatment</td><td align="center" valign="top" rowspan="1" colspan="1">142/1327 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">8/44 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">6/75 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">69/1185 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">6/142 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Household data</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Number of persons at home, median [IQR]</td><td align="center" valign="top" rowspan="1" colspan="1">6 [4&#x02013;9]</td><td align="center" valign="top" rowspan="1" colspan="1">7 [4&#x02013;8]</td><td align="center" valign="top" rowspan="1" colspan="1">7 [5&#x02013;9]</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Household TB contact<sup><xref rid="TFN8" ref-type="table-fn">#</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">562/1309 (43)</td><td align="center" valign="top" rowspan="1" colspan="1">24/42 (57)</td><td align="center" valign="top" rowspan="1" colspan="1">42/77 (55)</td><td align="center" valign="top" rowspan="1" colspan="1">35/747 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">42/562 (7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Household contact or suspect</td><td align="center" valign="top" rowspan="1" colspan="1">671/1174 (57)</td><td align="center" valign="top" rowspan="1" colspan="1">28/39 (72)</td><td align="center" valign="top" rowspan="1" colspan="1">51/69 (74)</td><td align="center" valign="top" rowspan="1" colspan="1">18/503 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">51/671 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02a7e;5 persons in home</td><td align="center" valign="top" rowspan="1" colspan="1">750/1039 (72)</td><td align="center" valign="top" rowspan="1" colspan="1">24/33 (73)</td><td align="center" valign="top" rowspan="1" colspan="1">48/60 (80)</td><td align="center" valign="top" rowspan="1" colspan="1">12/289 (4)</td><td align="center" valign="top" rowspan="1" colspan="1">48/750 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Contact with death on anti-tuberculosis treatment</td><td align="center" valign="top" rowspan="1" colspan="1">223/1258 (18)</td><td align="center" valign="top" rowspan="1" colspan="1">7/42 (17)</td><td align="center" valign="top" rowspan="1" colspan="1">18/77 (23)</td><td align="center" valign="top" rowspan="1" colspan="1">59/1035 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">18/223 (8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Patient disposition</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;In-patient/hospitalised</td><td align="center" valign="top" rowspan="1" colspan="1">420/1104 (38)</td><td align="center" valign="top" rowspan="1" colspan="1">15/36 (42)</td><td align="center" valign="top" rowspan="1" colspan="1">20/64 (31)</td><td align="center" valign="top" rowspan="1" colspan="1">44/684 (6)</td><td align="center" valign="top" rowspan="1" colspan="1">20/420 (5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>*</label><p id="P107">Data for each variable were not recorded for all subjects. The percentage indicates those who were positive using the microbiological technique, those who had the symptom or those for whom the symptom was recorded.</p></fn><fn id="TFN4"><label>&#x02020;</label><p id="P108">Of the total cohort, 84/1394 (6%) were microbiologically diagnosed with TB (culture).</p></fn><fn id="TFN5"><label>&#x02021;</label><p id="P109">Of those AFB-positive, 17/47(36%) were also TB culture-positive.</p></fn><fn id="TFN6"><label>&#x000a7;</label><p id="P110">To ensure validity, we limited the analysis of &#x02018;chest pain&#x02019; to children aged &#x02a7e;5 years.</p></fn><fn id="TFN7"><label>&#x000b6;</label><p id="P111">Antibiotics for the current complaint.</p></fn><fn id="TFN8"><label>#</label><p id="P112">Household contact with either cough or weight loss.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="landscape"><label>Table 3</label><caption><p id="P113">Individual variables documented at presentation in relevant risk groups to diagnose microbiologically confirmed pulmonary TB in children (<italic>n</italic> = 84)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th rowspan="3" align="left" valign="bottom" colspan="1">Individual variables at presentation</th><th rowspan="2" colspan="2" align="center" valign="bottom">Low-risk Non-HIV-infected<xref rid="TFN9" ref-type="table-fn">*</xref> aged &#x02a7e;3 years<hr/></th><th colspan="4" align="center" valign="bottom" rowspan="1">High-risk<hr/></th></tr><tr><th colspan="2" align="center" valign="bottom" rowspan="1">Non-HIV-infected aged &#x0003c;3 years<hr/></th><th colspan="2" align="center" valign="bottom" rowspan="1">HIV-infected aged &#x0003c;3 years<hr/></th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Sensitivity %</th><th align="center" valign="middle" rowspan="1" colspan="1">Specificity %</th><th align="center" valign="middle" rowspan="1" colspan="1">Sensitivity %</th><th align="center" valign="middle" rowspan="1" colspan="1">Specificity %</th><th align="center" valign="middle" rowspan="1" colspan="1">Sensitivity %</th><th align="center" valign="middle" rowspan="1" colspan="1">Specificity %</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight loss<sup><xref rid="TFN10" ref-type="table-fn">&#x02020;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">54</td><td align="center" valign="top" rowspan="1" colspan="1">70</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">41</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cough &#x0003e; 14 days<sup><xref rid="TFN11" ref-type="table-fn">&#x02021;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">88</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fever &#x0003e;14 days<sup><xref rid="TFN12" ref-type="table-fn">&#x000a7;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="top" rowspan="1" colspan="1">63</td><td align="center" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">64</td><td align="center" valign="top" rowspan="1" colspan="1">59</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Night sweats &#x0003e;14 days<sup><xref rid="TFN13" ref-type="table-fn">&#x000b6;</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">59</td><td align="center" valign="middle" rowspan="1" colspan="1">60</td><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">62</td><td align="center" valign="middle" rowspan="1" colspan="1">65</td><td align="center" valign="middle" rowspan="1" colspan="1">56</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fatigue &#x0003e;14 days<sup><xref rid="TFN14" ref-type="table-fn">#</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">25</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">65</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Poor appetite &#x0003e;14 days</td><td align="center" valign="top" rowspan="1" colspan="1">41</td><td align="center" valign="middle" rowspan="1" colspan="1">66</td><td align="center" valign="top" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">68</td><td align="center" valign="top" rowspan="1" colspan="1">48</td><td align="center" valign="top" rowspan="1" colspan="1">65</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chest pain &#x0003e;14 days<xref rid="TFN15" ref-type="table-fn">**</xref></td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">75</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">89</td><td align="center" valign="top" rowspan="1" colspan="1">58</td><td align="center" valign="top" rowspan="1" colspan="1">76</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Haemoptysis<sup><xref rid="TFN16" ref-type="table-fn">&#x02020;&#x02020;</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">94</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">99</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">97</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Household contact<sup><xref rid="TFN17" ref-type="table-fn">&#x02021;&#x02021;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">56</td><td align="center" valign="top" rowspan="1" colspan="1">45</td><td align="center" valign="top" rowspan="1" colspan="1">55</td><td align="center" valign="top" rowspan="1" colspan="1">59</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">71</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Combined symptoms</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02a7e;2 symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">94</td><td align="center" valign="top" rowspan="1" colspan="1">23</td><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">24</td><td align="center" valign="top" rowspan="1" colspan="1">86</td><td align="center" valign="top" rowspan="1" colspan="1">19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02a7e;3 symptoms</td><td align="center" valign="top" rowspan="1" colspan="1">71</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="middle" rowspan="1" colspan="1">82</td><td align="center" valign="top" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">86</td><td align="center" valign="top" rowspan="1" colspan="1">36</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Death of a family member on anti-tuberculosis treatment</td><td align="center" valign="top" rowspan="1" colspan="1">31</td><td align="center" valign="top" rowspan="1" colspan="1">81</td><td align="center" valign="top" rowspan="1" colspan="1">27</td><td align="center" valign="top" rowspan="1" colspan="1">85</td><td align="center" valign="top" rowspan="1" colspan="1">18</td><td align="center" valign="top" rowspan="1" colspan="1">82</td></tr></tbody></table><table-wrap-foot><fn id="TFN9"><label>*</label><p id="P114">All patients diagnosed with TB were offered HIV testing as part of Botswana&#x02019;s National HIV and TB guidelines&#x02014;subjects with unknown HIV status were not included in this analysis.</p></fn><fn id="TFN10"><label>&#x02020;</label><p id="P115">Unexplained weight loss indicates &#x02a7e;5% reduction in weight compared with the highest weight recorded in last 3 months, reported by the parent/care giver.</p></fn><fn id="TFN11"><label>&#x02021;</label><p id="P116">Persistent or non-remitting cough for &#x0003e;2 weeks.</p></fn><fn id="TFN12"><label>&#x000a7;</label><p id="P117">Persistent (&#x0003e;2 weeks) and unexplained fever (&#x0003e;38&#x000b0;C) as reported by the parent/care giver.</p></fn><fn id="TFN13"><label>&#x000b6;</label><p id="P118">Sweating in excess of other children the same age as reported by the care giver.</p></fn><fn id="TFN14"><label>#</label><p id="P119">Perceived decrease in playfulness or activity as reported by the parent/care giver.</p></fn><fn id="TFN15"><label>**</label><p id="P120">As reported by the child or care giver.</p></fn><fn id="TFN16"><label>&#x02020;&#x02020;</label><p id="P121">Presence of blood in the sputum (not haematemesis or a nose bleed).</p></fn><fn id="TFN17"><label>&#x02021;&#x02021;</label><p id="P122">Exposure to an adult TB index case in the household in the preceding 24 months.</p></fn><fn id="TFN18"><p id="P123">HIV = human immunodeficiency virus; TB = tuberculosis.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table 4</label><caption><p id="P124">Frequency and description of adverse events of subjects undergoing sputum induction (<italic>n</italic> = 1174)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Adverse event</th><th align="center" valign="top" rowspan="1" colspan="1">Events <italic>n</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Vomiting</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nose bleed</td><td align="center" valign="top" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Increased coughing</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oxygen desaturations (to 90% post procedure)</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wheeze</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Total</td><td align="left" valign="top" rowspan="1" colspan="1">15 adverse events<xref rid="TFN19" ref-type="table-fn">*</xref></td></tr></tbody></table><table-wrap-foot><fn id="TFN19"><label>*</label><p id="P125">A total of 9 patients experienced adverse events: 6 experienced two events (5 vomiting and nose bleed, 1 vomiting and wheeze).</p></fn></table-wrap-foot></table-wrap><table-wrap id="T5" position="float" orientation="landscape"><label>Table 5</label><caption><p id="P126">Clinical characteristics of children with MOTT (<italic>n</italic> = 5)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Subject</th><th align="left" valign="top" rowspan="1" colspan="1">Sex</th><th align="left" valign="top" rowspan="1" colspan="1">Age</th><th align="left" valign="top" rowspan="1" colspan="1">HIV status</th><th align="left" valign="top" rowspan="1" colspan="1">PPD test</th><th align="left" valign="top" rowspan="1" colspan="1">MOTT species</th><th align="left" valign="top" rowspan="1" colspan="1">Signs and symptoms</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">7 years</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">Night sweats, persistent unremitting cough and intermittent pyrexia &#x0003e;2 weeks. No household TB contacts</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">2 months</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>M. fortuitum</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Persistent unremitting cough, intermittent pyrexia, night sweats, reduced playfulness &#x0003e;2 weeks. Positive household TB contact</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">11 years</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>M. intracellulare</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Asymptomatic, referred for sputum induction as positive household TB contact. Contact had persistent cough, weight loss and was on anti-tuberculosis treatment</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="left" valign="top" rowspan="1" colspan="1">6 years</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td><td align="left" valign="top" rowspan="1" colspan="1"><italic>M. gordoniae</italic></td><td align="left" valign="top" rowspan="1" colspan="1">Persistent unremitting cough, night sweats &#x0003e;2 weeks and recurrent chest pain. No positive household TB contacts</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="left" valign="top" rowspan="1" colspan="1">6 years</td><td align="left" valign="top" rowspan="1" colspan="1">Positive</td><td align="left" valign="top" rowspan="1" colspan="1">Positive</td><td align="left" valign="top" rowspan="1" colspan="1">Unknown</td><td align="left" valign="top" rowspan="1" colspan="1">Weight loss and positive household TB contact</td></tr></tbody></table><table-wrap-foot><fn id="TFN20"><label>*</label><p id="P127">PPD &#x0003e;10 mm was considered positive if non-HIV-infected or &#x0003e;5 mm if HIV-infected or severely malnourished.</p></fn><fn id="TFN21"><p id="P128">MOTT = mycobacteria other than tuberculosis; HIV = human immunodeficiency virus; PPD = purified protein derivative; TB = tuberculosis.</p></fn></table-wrap-foot></table-wrap></floats-group></article>